George Astras, Director of Medical Oncology at the American Medical Center and Ippokrateion Hospital, shared a post on LinkedIn:
“It is absolutely a historic moment. The presentation of the RASolute 302 trial results at the ASCO plenary session is being widely called a ‘transformative’ and paradigm-shifting milestone in oncology.
For decades, the KRAS oncogene was famously deemed ‘undruggable’, and progressive pancreatic cancer (mPDAC) has remained one of medicine’s most stubborn, heartbreaking challenges. Watching a drug finally break through that wall is nothing short of breathtaking.
The sheer scale of the data explains exactly why the room was on its feet giving a standing ovation and a breath of fresh air in Pancreatic Cancer.”
You can also read: Is RAS No Longer Undruggable? Discussions on RASolute Trial That Earned Standing Ovation at ASCO26
